Inodilators in septic shock: should these be used?

Area of Science:

• Critical Care Medicine
• Cardiology
• Pharmacology

Background:

• Septic shock is characterized by vasodilation, hypovolemia, myocardial dysfunction, and altered tissue perfusion.
• Current sepsis management guidelines recommend inotropes for myocardial dysfunction, indicated by low cardiac output or persistent hypoperfusion.
• Inotropes are key components of resuscitation protocols aimed at restoring tissue perfusion.

Purpose of the Study:

• To review the evidence on the use of inotropes and inodilators in sepsis and septic shock.
• To evaluate the impact of inotropes on macro- and microcirculation in septic shock.
• To assess the controversial role of inotropes in improving clinical outcomes in septic shock.

Main Methods:

• Review of physiological studies and clinical trials on inotropes in sepsis.
• Analysis of data on hemodynamic effects (macrocirculation, splanchnic circulation, microcirculation).
• Evaluation of clinical outcomes, including mortality and organ dysfunction, associated with inotrope use.

Main Results:

• Inotropes show potential benefits on macro hemodynamics, especially with coexisting myocardial dysfunction.
• Variable effects of inotropes on regional splanchnic circulation and microvascular distribution have been reported.
• Clinical outcomes associated with dobutamine and levosimendan in sepsis are controversial, with mixed results on mortality and organ dysfunction.

Conclusions:

• The use of inotropes in septic shock is controversial, with evidence supporting hemodynamic improvement but not consistently favorable clinical outcomes.
• Recent meta-analyses suggest potential mortality benefits from inodilators, particularly in patients with low cardiac output.
• Further research is essential to definitively establish the role and optimal use of inotropes in managing sepsis and septic shock.